Cormedix Inc (CRMD) Stock Price, Quote & News

Company Profile

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was in...

Industry: Biotechnology

Sector: Healthcare

Phone: 908 517 9500

Website: cormedix.com

Address:

389 Interpace Pkwy, Suite 450, Parsippany, United States

golfguy42360 May. 13 at 8:20 PM

$CRMD I need a pump tomorrow to 8.25 so I can get the fuck out until the shorts leave.

0 · Reply

TwongStocks May. 13 at 8:07 PM

$CRMD TLPH ER is out. NEPHRO CRRT clinical study expected to be completed this year. Same status as TLPH's previous ER. No enrollment updates to the NEPHRO study.

0 · Reply

flabb May. 13 at 7:47 PM

$CRMD added 7.50

0 · Reply

Miketj May. 13 at 7:25 PM

$CRMD boring zzzz. On the not so boring side banked on SNOW and going for a hopefully profitable play in SOFI… GLA

0 · Reply

Noname2022 May. 13 at 7:09 PM

$AKBA $CRMD https://www.morningstar.com/news/pr-newswire/20260513da57818/us-renal-care-associate-chief-medical-officer-geoffrey-a-block-md-fasn-awarded-2026-aakp-medal-of-excellence-for-lifetime-contributions-to-kidney-care

0 · Reply

ReturnOfEsquire May. 13 at 6:35 PM

$CRMD Need a couple of these tonight to calm the nerves...

1 · Reply

look_at_that_ May. 13 at 5:25 PM

$CRMD institutional ownership up to 58.5% from low 50s

1 · Reply

golfguy42360 May. 13 at 4:18 PM

$CRMD Short % went up a little bit would love to se them get burnt tomorrow but I don't think its happening.

0 · Reply

Missing_Link_ May. 13 at 3:59 PM

$CRMD 520 7418

0 · Reply

Derek22us May. 13 at 3:45 PM

$CRMD Amazing job of the by the sheister scavengers yesterday and they continue the capping and throttling of the share price with their 700 and 1100 share in box to out box and matching buy and sell lots to take down and hold down the share price.

0 · Reply

CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026

2026-04-28T19:40:19.000Z - 15 days ago

Citizens healthcare analysts hold an analyst/industry conference call

2026-04-28T11:56:23.000Z - 15 days ago

CorMedix price target raised to $14 from $13 at RBC Capital

2026-04-27T12:05:37.000Z - 16 days ago

CorMedix announces ReSPECT clinical trial met primary endpoint

Apr 27, 2026, 7:30 AM EDT - 16 days ago

CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients

Apr 14, 2026, 3:00 PM EDT - 4 weeks ago

CorMedix Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 7, 2026, 8:30 AM EDT - 5 weeks ago

CorMedix to Participate in Needham Virtual Healthcare Conference

Mar 11, 2026, 9:35 AM EDT - 2 months ago

CorMedix Transcript: The Citizens Life Sciences Conference 2026

Mar 10, 2026, 1:00 PM EDT - 2 months ago

CorMedix Transcript: Leerink Global Healthcare Conference 2026

2026-03-06T22:20:58.000Z - 2 months ago

CorMedix affirms FY26 revenue view of $300M-$320M, consensus $308.7M

2026-03-06T17:05:52.000Z - 2 months ago

CorMedix price target lowered to $13 from $15 at Leerink

Mar 5, 2026, 12:58 PM EST - 2 months ago

CorMedix stock drops after earnings: is this dip a buy before key catalyst?

Mar 5, 2026, 8:30 AM EST - 2 months ago

CorMedix Earnings Call Transcript: Q4 2025

2026-03-05T12:36:24.000Z - 2 months ago

CorMedix reports Q4 EPS 16c vs 20c last year

Mar 5, 2026, 7:30 AM EST - 2 months ago

CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 2, 2026, 8:30 AM EST - 2 months ago

CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026

Feb 12, 2026, 8:30 AM EST - 3 months ago

CorMedix to Participate in Upcoming Investor Conferences

Feb 10, 2026, 1:00 PM EST - 3 months ago

CorMedix Transcript: Investor Day 2026

2026-02-02T13:35:15.000Z - 3 months ago

CorMedix board authorizes share repurchase program of up to $75M

Feb 2, 2026, 8:30 AM EST - 3 months ago

CorMedix Therapeutics Announces Share Repurchase Program

Jan 29, 2026, 8:30 AM EST - 3 months ago

CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026

2026-01-23T11:10:42.000Z - 3 months ago

CorMedix price target lowered to $13 from $18 at H.C. Wainwright

2026-01-21T11:35:46.000Z - 4 months ago

CorMedix price target lowered to $13 from $22 at RBC Capital

Jan 12, 2026, 7:30 PM EST - 4 months ago

CorMedix Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 9, 2026, 8:30 AM EST - 4 months ago

CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 8, 2026, 1:37 PM EST - 4 months ago

Why is CorMedix stock crashing today: is it worth buying on the dip?

2026-01-08T17:45:22.000Z - 4 months ago

CorMedix price target lowered to $16 from $20 at Truist

2026-01-08T13:17:12.000Z - 4 months ago

CorMedix sees FY26 revenue $300M-$320M

2026-01-08T13:17:02.000Z - 4 months ago

CorMedix CEO Joseph Todisco signs extended employment contract

2026-01-08T13:16:04.000Z - 4 months ago

CorMedix appoints Mike Seckler as CCO

2026-01-08T13:10:42.000Z - 4 months ago

CorMedix sees Q4 revenue $127M, consensus $127.52M

Jan 8, 2026, 8:05 AM EST - 4 months ago

CorMedix Therapeutics Announces Leadership and Board Updates

Jan 8, 2026, 8:00 AM EST - 4 months ago

CorMedix Therapeutics Announces Preliminary Fourth Quarter and Full Year 2025 Results and Provides Business Updates

2025-12-18T13:11:39.000Z - 5 months ago

CorMedix announces interim results for DefenCath

Dec 18, 2025, 8:00 AM EST - 5 months ago

CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath

Nov 12, 2025, 4:05 PM EST - 6 months ago

Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update

TLPH

Nov 12, 2025, 8:30 AM EST - 6 months ago

CorMedix Earnings Call Transcript: Q3 2025

Nov 12, 2025, 7:30 AM EST - 6 months ago

CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance

Oct 31, 2025, 8:30 AM EDT - 6 months ago

CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025

Oct 23, 2025, 8:30 AM EDT - 7 months ago

CorMedix Inc. Receives Innovative Technology Designation From Vizient for DefenCath

Oct 22, 2025, 4:05 PM EDT - 7 months ago

Halper Sadeh LLC Encourages CorMedix Inc. Shareholders to Contact the Firm to Discuss Their Rights

Oct 20, 2025, 9:42 AM EDT - 7 months ago

CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why

CELC RANI RAPT

Oct 20, 2025, 7:30 AM EDT - 7 months ago

CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue Guidance

Sep 29, 2025, 8:30 AM EDT - 8 months ago

CorMedix Announces Completion of Enrollment in Phase III ReSPECT Clinical Trial for REZZAYO

Sep 10, 2025, 10:45 AM EDT - 8 months ago

CorMedix Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 8:30 AM EDT - 8 months ago

CorMedix Announces Strategic Minority Investment in Talphera

TLPH

Sep 8, 2025, 8:30 AM EDT - 8 months ago

Talphera Announces Private Placement Financing of up to $29 Million Priced At-the Market

TLPH

Sep 5, 2025, 8:35 AM EDT - 8 months ago

CorMedix Transcript: Cantor Global Healthcare Conference 2025

Sep 2, 2025, 7:30 AM EDT - 9 months ago

CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team

Aug 7, 2025, 10:49 AM EDT - 9 months ago

CorMedix to Buy Melinta Therapeutics for $300 Million

Aug 7, 2025, 7:10 AM EDT - 9 months ago

Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring Its Portfolio Value and Industry Leadership

Aug 7, 2025, 7:00 AM EDT - 9 months ago

CorMedix to acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence in Acute Care Settings

Aug 7, 2025, 7:00 AM EDT - 9 months ago

Cormedix Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update

Jun 27, 2025, 8:00 AM EDT - 11 months ago

CorMedix Inc. Announces Pricing of Public Offering of Common Stock

Jun 26, 2025, 4:01 PM EDT - 11 months ago

CorMedix Inc. Announces Proposed Public Offering of Common Stock

Jun 23, 2025, 7:30 AM EDT - 11 months ago

CorMedix inc. Announces Customer Implementation

Jun 5, 2025, 3:45 PM EDT - 1 year ago

CorMedix Transcript: Jefferies Global Healthcare Conference 2025

May 30, 2025, 8:30 AM EDT - 1 year ago

CorMedix Inc. To Participate In The Jefferies Global Healthcare Conference

May 21, 2025, 3:05 PM EDT - 1 year ago

CorMedix Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

CorMedix Inc. to Participate in the RBC Global Healthcare Conference

May 8, 2025, 11:00 AM EDT - 1 year ago

CorMedix Transcript: The Citizens JMP Life Sciences Conference 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

CorMedix Earnings Call Transcript: Q1 2025

May 6, 2025, 7:30 AM EDT - 1 year ago

CorMedix Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 29, 2025, 8:30 AM EDT - 1 year ago

CorMedix Inc. to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 6, 2025

Apr 8, 2025, 2:15 PM EDT - 1 year ago

CorMedix Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 8, 2025, 7:30 AM EDT - 1 year ago

Cormedix Inc. Announces Preliminary First Quarter 2025 Results and Raises H1 2025 Net Sales Guidance

Apr 2, 2025, 8:30 AM EDT - 1 year ago

CorMedix Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 25, 2025, 8:30 AM EDT - 1 year ago

CorMedix Earnings Call Transcript: Q4 2024

Mar 25, 2025, 7:30 AM EDT - 1 year ago

CorMedix Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 18, 2025, 8:30 AM EDT - 1 year ago

CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025

Mar 10, 2025, 1:00 PM EDT - 1 year ago

CorMedix Transcript: Leerink’s Global Healthcare Conference 2025

Jan 7, 2025, 7:30 AM EST - 1 year ago

CorMedix Inc. Announces Preliminary Fourth Quarter 2024 Results and Provides Business Update

golfguy42360 May. 13 at 8:20 PM

$CRMD I need a pump tomorrow to 8.25 so I can get the fuck out until the shorts leave.

0 · Reply

TwongStocks May. 13 at 8:07 PM

$CRMD TLPH ER is out. NEPHRO CRRT clinical study expected to be completed this year. Same status as TLPH's previous ER. No enrollment updates to the NEPHRO study.

0 · Reply

flabb May. 13 at 7:47 PM

$CRMD added 7.50

0 · Reply

Miketj May. 13 at 7:25 PM

$CRMD boring zzzz. On the not so boring side banked on SNOW and going for a hopefully profitable play in SOFI… GLA

0 · Reply

Noname2022 May. 13 at 7:09 PM

0 · Reply

ReturnOfEsquire May. 13 at 6:35 PM

$CRMD Need a couple of these tonight to calm the nerves...

1 · Reply

look_at_that_ May. 13 at 5:25 PM

$CRMD institutional ownership up to 58.5% from low 50s

1 · Reply

golfguy42360 May. 13 at 4:18 PM

$CRMD Short % went up a little bit would love to se them get burnt tomorrow but I don't think its happening.

0 · Reply

Missing_Link_ May. 13 at 3:59 PM

$CRMD 520 7418

0 · Reply

Derek22us May. 13 at 3:45 PM

0 · Reply

Derfzilla May. 13 at 3:36 PM

$CRMD

1 · Reply

flabb May. 13 at 3:28 PM

$IBRX $CLF $PLUG $CRMD $FIGS Break On through to the Other Side yeahh

1 · Reply

ReturnOfEsquire May. 13 at 2:58 PM

$CRMD While tomorrow isn't binary, a bad call could very well pin this down for 6-12 months more absent a significant catalyst. I don’t expect that, but it's a real possibility. Long term, I have no doubt this is an easy 3-4x from here, and especially now that Makary resigned, but I know nothing about his replacement. Still, can't get worse than Markary, I don't think.

0 · Reply

Hoddogwater May. 13 at 2:56 PM

$CRMD

0 · Reply

flabb May. 13 at 2:39 PM

$CRMD added 7.57

0 · Reply

flabb May. 13 at 2:27 PM

$PLUG power just gave me a ton of power and i was adding up t0 3.71 and added with the plug power to $CRMD 7.55

0 · Reply

flabb May. 13 at 2:22 PM

$CRMD 7.58 added and adding.

0 · Reply

flabb May. 13 at 2:17 PM

$CRMD still adding to crmd at 7.54 - 7.57 and would like to see 7.80 and then 8.00 going into tomorrows earning.s

0 · Reply

flabb May. 13 at 2:13 PM

$FIGS and $CRMD just been adding as buying power comes in now will be working on $NVAX 9.48 added and still adding 9.45 limit order in.

0 · Reply

ReturnOfEsquire May. 13 at 2:09 PM

$CRMD Great summary of what to expect tomorrow. https://finance.yahoo.com/sectors/healthcare/articles/cormedix-outlines-post-melinta-growth-130404067.html

0 · Reply

flabb May. 13 at 2:03 PM

$CRMD added 7.4855 and it popped at 7.49 7.50 7.51 and will still be adding anywhere under 7.68 and anywhere under 8.00

1 · Reply

btdb May. 13 at 2:02 PM

$CRMD 7.10 ish is the 50 day moving average. The shorts may be taking aim at it post guidance. Without significantly upped guidance for h2 and 2027 we could trade significantly lower on the expectation of higher costs h2 for Rezzayo Prophylaxis, TPN, etc. and potentially negative eps h2 / 2027. Rezzayo Prophylaxis could be great but I don’t believe it gives us any traction until it’s on the market and predictable, hence the third quarter on the market or later. GUIDANCE is the key here.

0 · Reply

Market Cap	600.87M
Revenue (ttm)	311.71M
Net Income (ttm)	163.06M
EPS (ttm)	N/A
PE Ratio	4.50
Forward PE	18.00
Profit Margin	52.31%
Debt to Equity Ratio	0.00

Volume	1,123,570
Avg Vol	1,271,658
Day's Range	N/A - N/A
Shares Out	78.44M
Stochastic %K	11%
Beta	1.46
Analysts	Strong Sell
Price Target	$15.00